Person:
AYDINER, ELİF

Loading...
Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Organizational Unit

Job Title

Last Name

AYDINER

First Name

ELİF

Name

Search Results

Now showing 1 - 2 of 2
  • Publication
    Oxidative Burst with Dihydrorhodamine Test: Reference Values in Healthy Controls
    (TURKISH SOC IMMUNOLOGY, 2015) ÖZEN, AHMET OĞUZHAN; Cicekkoku, Dilek; Ogulur, Ismail; Karakoc-Aydiner, Elif; Baris, Safa; Kiykim, Ayca; Ozen, Ahmet; Barlan, Ist
    Objectives: In this study, we report reference data of stimulation index (SI) and variation coefficient (VC) data in dihydrorhodamine test in healthy controls. Materials and methods: Two hundred ten healthy controls without primary immunodeficiency warning signs and chronic disease were enrolled in this study. Evaluation was performed in 184 individuals (67 females, 117 males; mean age 9.0 +/- 9.6 years; range 0.3 to 59.2 years) with full data analysis. 2 mL peripheral blood samples were taken from healthy controls and lysis of erythrocytes was provided in flow cytometer tubes. The cells were washed twice with Hank's buffered salt solution (HBSS) and incubated at 37 degrees C for 14 minutes in the 50 ng/mL phorbol myristate acetate (PMA) stimulation. The cells were immediately evaluated using gating granulocytes in the BD FACS Calibur flow cytometer tool. The SI was calculated by dividing the ratio of geometric mean of fluorescence intensities obtained from PMA stimulated neutrophils to non-stimulated values. In flow cytometry, VC values of fluorescence intensity on the x-axis of histogram were obtained in PMA stimulated cells. Results: In the healthy controls, SI values were observed to vary ranging between 20.1 and 125.2 (mean 36.75 +/- 18.3). In the same series, VC values were between 9.9-25.2 (mean 18.2 +/- 3.7). Conclusion: Besides the use of a diagnostic test for chronic granulomatous disease, DHR test is useful in identifying the inheritance type of this disease and carriers. Values presented herein can be used as reference data for the assessment of patients and carriers.
  • PublicationOpen Access
    Lymphocyte Functions in Patients with Chronic Granulomatous Disease and Carrier Individuals
    (TURKISH SOC IMMUNOLOGY, 2019) ÖZEN, AHMET OĞUZHAN; Ogulur, Ismail; Baris, Ezgi; Kiykim, Ayca; Baser, Dilek; Akgun, Gamze; Ozen, Ahmet; Baris, Safa; Karakoc-Aydiner, Elif
    Introduction: Chronic granulomatous disease (CGD) is classically known as phagocytic system disease. However, in recent years, the observation of the development of autoimmunity, colitis-like findings during follow-up has suggested that the acquired immune system may also be defective. The aim of this project is to investigate the percent of T and B lymphocytes, and function of T lymphocytes in patients with CGD and carriers. Material and Methods: Eleven patients followed for CGD (3 X-CGD, 8 OR-CGD) in our clinic and 6 carrier mothers of OR-CGD were included into the study. The percentages of lymphocytes and their subtypes, lymphocyte proliferation, regulator T cell (Treg), intracellular cytokine content of patients with CDC and carriers we re determined in comparison to healthy controls. Results: There was no statistically significant difference in percentages of T cell, B cell and NK cell and subtypes of T and B cells in the mothers of patients compared to age marched healthy controls. The percentage of naive B cells was significantly higher in the patients with CGD compared to those of healthy subjects (p<0.001). There were no significant differences in lymphocyte proliferation, Treg cell percentage, intracellular IL-17 levels, but IFN-gamma levels were significantly increased in both patients with CDG (p=0.030) and carriers (p=0.038) when compared with age-matched healthy controls. Conclusion: Increased naive B cells were found in CGD patients. High levels of IFN-gamma in patients and carriers need to be further evaluated by further studies. In addition, the normal percentages of Treg and IL-21 in the carriers as in healthy subjects may be offered as the protective mechanism for autoimmunity.